A REIT With Great V...
Health Care: Drugs
Anthera Pharmaceuticals Inc. (ANTH: NASDAQ)
$0.60 0.00 | 0.00%
05/22/13 - 03:59 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -59.40M | -95.34M | -40.41M | -12.20M |
| Operating Gains/Losses | 46.00K | -8.00K | 0.00 | 946.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -12.23M | 13.57M | 2.66M | -212.62K |
| (Decrease) Increase In Other Current Liabilities | -4.40M | 4.12M | 2.76M | -385.07K |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | 0.00 | -5.00M |
| Other Non-Cash Items | 960.00K | 2.42M | 8.17M | 341.63K |
| Net Cash From Continuing Operations | -73.64M | -73.07M | -27.78M | -17.17M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -73.64M | -73.07M | -27.78M | -17.17M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 400.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 7.10M | 26.31M | 1.61M | 0.00 |
| Purchases of Property, Plant & Equipment | -207.00K | -1.35M | -21.57K | -3.85K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -10.67M | -4.74M | -24.95M | 0.00 |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 40.00K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -3.78M | 20.23M | -23.36M | 36.55K |
| Issuance of Debt | 0.00 | 24.70M | 0.00 | 13.40M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 35.76M | 54.61M | 90.99M | 15.27K |
| Repayment of Long-Term Debt | -4.47M | 0.00 | -210.28K | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -37.00K | -879.00K | -3.25M | -371.20K |
| Net Cash From Financing Activities | 31.26M | 78.43M | 87.53M | 13.04M |
| Effect of Exchange Rate Changes | -31.00K | 0.00 | -164.97K | 0.00 |
| Net Change in Cash & Cash Equivalents | -46.19M | 25.59M | 36.23M | -4.09M |
Portfolios with ANTH
- Portfolio NameUser Type
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- Usertest1123
- ContributorStocks Under-$10 Setting Up...
- UserStan/Gino
- ContributorStocks With Big Insider Buy...
- UserPoorprae's Stock Picks
- ContributorStocks Under-$10 Moving Hig...
- UserPortfoio1
- ContributorBreakout Stocks Of The Week...
Latest ANTH Headlines from TheStreet
- 5 Stocks Insiders Are Scooping Up 01.30.13 | 12:01 pm
- Top Insider Trades: NVR FIZZ COST ANTH 01.30.13 | 09:01 am
- Biotech Stock Mailbag: Aveo, Anthera, Amarin, MAP Pharma 11.20.12 | 10:11 am
- 5 Stocks Under $10 Set to Trade Higher in November 11.01.12 | 01:11 pm
- 5 Biotech Stocks Under $5 Making Bullish Moves 06.21.12 | 01:06 pm
- 7 Stocks Under $10 Streaking Higher 06.07.12 | 04:06 pm
- 8 Stocks Under $10 Soaring Higher 05.10.12 | 01:05 pm
- Stocks to Watch: ReneSola, UPS, AIG (Update 1) 03.16.12 | 07:03 am
- For Biotech, 'Fail' is Making a Big Comeback 03.12.12 | 08:03 am
- FirstWind IPO -- Gone With the Wind? 10.25.10 | 08:10 am
Press Releases for ANTH
- Anthera Pharmaceuticals Announces Additional Data From Phase 2b PEARL-SC Blisibimod Study - PR Newswire 05.07.13 | 04:05 pm
- Anthera Announces First Quarter 2013 Financial Report And Conference Call - PR Newswire 05.03.13 | 02:05 pm
- Anthera Refinances Existing Debt With New $20 Million Credit Facility And Secures $18.5 Million Committed Equity Financing Facility - PR Newswire 04.05.13 | 05:04 pm
- Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study In Lupus With Blisibimod - PR Newswire 03.27.13 | 04:03 pm
- Anthera Announces Data From The Phase 2b PEARL-SC Study Will Be Presented At The 10th International Congress On Systemic Lupus Erythematosus - PR Newswire 03.22.13 | 08:03 am
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of Anthera Pharmaceuticals, Inc. In Connection With Executive Compensation - Business Wire 02.13.13 | 11:02 am
- Faruqi & Faruqi, LLP Is Investigating Anthera Pharmaceuticals Incorporated On Behalf Of Its Shareholders - ANTH - PR Newswire 02.13.13 | 08:02 am
- Anthera Pharmaceuticals To Present At The 2013 Leerink Global Healthcare Conference - PR Newswire 02.07.13 | 05:02 pm
- Anthera Pharmaceuticals Announces Departure Of Georgina Kilfoil - PR Newswire 02.05.13 | 08:02 am
- Anthera Pharmaceuticals Announces Completion Of Public Offering Of Common Stock - PR Newswire 01.30.13 | 09:01 am
Partner Headlines for ANTH
- Benzinga's Microcap Movers for Friday August 24, 2012 - Benzinga 08.26.12 | 09:08 am
- Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock; 33M Shares at $1.00/Share - Benzinga 07.19.12 | 09:07 am
- Healthcare Biz Rewind: StemCells DOUBLES Its Value, Anthera POPS - Wall St. Cheat Sheet 07.18.12 | 09:07 am
- Gilead Sciences RECEIVES FDA Approval and 4 Hot Stocks Driving the Market Today - Wall St. Cheat Sheet 07.17.12 | 01:07 pm
- Ultimate Market Recap: Yahoo Down on Mayer's First Day, Mattel Makes Out Well for Q2 - Wall St. Cheat Sheet 07.17.12 | 10:07 am
- 4 Reasons To Buy Anthera Pharmaceuticals - Seeking Alpha 07.16.12 | 09:07 am
- Vertex Pharmaceuticals CRASHES 16% with 3 NASDAQ Top Percentage Losers - Wall St. Cheat Sheet 06.29.12 | 10:06 am
- Today's Market News To Trade On: 5 Stocks Moving On News - Seeking Alpha 06.29.12 | 09:06 am
- Nike SLAPPED with a DOWNGRADE Joining These 3 Stocks - Wall St. Cheat Sheet 06.29.12 | 04:06 am
- Healthcare Business Recap: Orexigen RIDES Arena, Anthera IMPLODES - Wall St. Cheat Sheet 06.28.12 | 08:06 am
